No Head-To-Head Trial, Two Real Differences
There is no head-to-head randomized trial comparing the Wegovy pill against the Wegovy injection, so published evidence does not identify a definitive winner on weight loss efficacy. Patients evaluating the choice between the tablet and the injection must look instead at each product's individual clinical data and daily administration demands.
In its 64-week clinical trial, the 25 mg tablet produced a mean body weight change of -13.6% compared to -2.4% on placebo across all randomized participants. Among participants who adhered fully to treatment, the tablet delivered a 16.6% mean weight reduction. Novo Nordisk describes this performance as similar to injectable Wegovy 2.4 mg, but that claim represents a manufacturer cross-trial characterization rather than a direct head-to-head trial finding.
The verifiable differences between the two options center on daily routines and approved indications. The subcutaneous injection is administered once weekly at any time of day, with or without food. The tablet requires daily administration every morning on an empty stomach with four ounces of water or less, followed by a strict 30-minute wait before consuming any food, liquid, or other pills. Furthermore, the injection carries approved indications for pediatric patients aged 12 and older and adults with noncirrhotic MASH, whereas the tablet holds neither indication.
Wegovy Pill vs Injection: Key Dimensions Side by Side
Both formulations deliver semaglutide to activate GLP-1 receptors, but their delivery routes create distinct dosing schedules, titration speeds, and clinical indications. When weighing the tablet-versus-pen decision, patients must assess whether daily oral administration fits their lifestyle better than a weekly injection. The table below outlines the core specifications established in the official DailyMed Wegovy label, which covers both formulations in a single document updated 18 June 2026.
| Dimension | Wegovy Pill (25 mg Tablet) | Wegovy Injection (2.4 mg) |
|---|---|---|
| Form | Oral tablet | Subcutaneous injection |
| Maintenance dose | 25 mg once daily | 2.4 mg once weekly (or 1.7 mg; up to 7.2 mg for weight) |
| Administration frequency | Once daily in the morning | Once weekly on the same day each week |
| Timing flexibility | Morning on an empty stomach | Any time of day |
| Food and water rules | Empty stomach with up to 4 ounces of water; wait 30 minutes before food or other pills | With or without meals |
| Available strengths | 1.5 mg, 4 mg, 9 mg, 25 mg | 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg (plus 7.2 mg HD) |
| Time to maintenance dose | 90 days (maintenance begins on day 91) | 16 weeks (maintenance begins at week 17) |
| Chronic weight management | Approved for adults with obesity, or overweight with a comorbid condition | Approved for adults with obesity, or overweight with a comorbid condition |
| Cardiovascular risk reduction | Approved for adults with established CVD and obesity or overweight | Approved for adults with established CVD and obesity or overweight |
| Pediatric coverage | Not approved for pediatric patients | Approved for patients aged 12 and older with obesity |
| Liver disease (MASH) indication | No MASH indication | Approved for noncirrhotic MASH with moderate to advanced liver fibrosis in adults |
What Each One's Own Trial Showed
Clinical trial evidence for the Wegovy tablet comes from Study 7, registered as NCT05564117 and designated OASIS 4 by Novo Nordisk, which evaluated 307 adults with obesity or overweight over 64 weeks. The FDA approved the 25 mg semaglutide tablets following this study, and Novo Nordisk announced the approval on 22 December 2025 as the first oral GLP-1 approved for weight management. In that announcement, the manufacturer stated an expectation to launch the tablet in the United States in early January 2026.
In this double-blind trial, participants were randomized in a 2:1 ratio, with 205 receiving the oral tablet escalated to 25 mg over 12 weeks and 102 receiving placebo, followed by a 52-week maintenance phase. The FDA label reports the treatment-policy estimand, which reflects outcomes across all randomized patients regardless of treatment adherence. In this primary analysis, the 25 mg tablet achieved a mean body weight reduction of -13.6% compared to -2.4% for placebo, reflecting a treatment difference of -11.2 percentage points (95% CI -13.6 to -8.8, p<0.0001).
A second figure comes from the trial-product estimand reported in Novo Nordisk's announcement, which evaluates participants who maintained adherence to the treatment regimen. In that analysis, the tablet delivered 16.6% mean weight loss. Novo Nordisk also reported that one in three people in OASIS 4 experienced 20% or greater weight loss of their body weight. Adverse reactions led to treatment discontinuation in 6.8% of patients receiving the 25 mg tablet compared to 5.9% receiving placebo.
No head-to-head randomized trial has compared the tablet against the injection, so there is no sound basis for putting a number on the difference between the two forms. Novo Nordisk states that weight loss achieved with the pill is similar to injectable Wegovy 2.4 mg, but that claim is an indirect cross-trial comparison rather than a head-to-head trial result.
The Daily Fasted Window Versus The Weekly Shot
The daily administration schedule represents the most significant functional distinction in this comparison. Under the official prescribing instructions, patients must take one Wegovy tablet orally once daily on an empty stomach in the morning. The tablet must be swallowed whole with plain water limited to four ounces or less, and patients must never take more than one tablet per day.
The physical properties of the tablet require strict handling rules. Patients must not split, crush, chew, or dissolve the tablet, and taking the dose with liquids other than plain water is prohibited. After swallowing the tablet, the patient must wait at least 30 minutes before eating food, drinking beverages, or taking any other oral medications. If a patient misses a dose, the label instructs them to skip the missed dose and take the next dose the following day.
These morning rules exist because of the pharmacokinetics of oral semaglutide. Oral tablets have an absolute bioavailability of roughly 1% to 2%, compared to 89% for subcutaneous injections. Maximum concentration occurs about one hour after an oral dose, whereas subcutaneous administration reaches peak concentration over one to three days.
The injectable formulation operates under completely different administration rules. Patients inject Wegovy once weekly, on the same day each week, at any time of day, with or without meals. The time of day and the injection site can be changed without modifying the dosage. For step-by-step guidance on handling the oral dose, review our instructions on how to take the Wegovy pill.
Time To The Maintenance Dose
The Wegovy pill reaches its full maintenance dosage sooner than the subcutaneous injection under standard titration schedules. Both formulations require stepped dose escalation to allow the patient to adjust to incretin therapy, but their titration schedules follow different timelines. The table below details each step of the escalation ladder from initiation to maintenance.
| Step | Wegovy Pill (25 mg Tablet) | Wegovy Injection (2.4 mg) |
|---|---|---|
| Step 1 | Days 1 to 30: 1.5 mg daily | Weeks 1 to 4: 0.25 mg weekly |
| Step 2 | Days 31 to 60: 4 mg daily | Weeks 5 to 8: 0.5 mg weekly |
| Step 3 | Days 61 to 90: 9 mg daily | Weeks 9 to 12: 1 mg weekly |
| Step 4 | Day 91 onward: 25 mg daily maintenance | Weeks 13 to 16: 1.7 mg weekly |
| Step 5 | Not applicable | Week 17 onward: 2.4 mg weekly maintenance |
The tablet advances through three intermediate strengths over 30-day intervals: 1.5 mg for days 1 to 30, 4 mg for days 31 to 60, and 9 mg for days 61 to 90. The patient reaches the 25 mg daily maintenance dose on day 91, completing 90 days of stepped escalation. If a patient cannot tolerate a dose during escalation, the label instructs clinicians to consider delaying dosage escalation.
The injection escalates in four-week intervals: 0.25 mg for weeks 1 to 4, 0.5 mg for weeks 5 to 8, 1 mg for weeks 9 to 12, and 1.7 mg for weeks 13 to 16. The patient reaches the recommended 2.4 mg maintenance dose at week 17. For adult chronic weight management, 1.7 mg is also an approved maintenance dose, and clinicians may increase the dose to a maximum of 7.2 mg weekly if 2.4 mg is tolerated for at least four weeks and additional weight reduction is needed. Learn more about the oral formulation's clinical background in our overview of the Wegovy pill.
Switching Between The Two Formulations
The prescribing information outlines explicit clinical protocols for transitioning patients between oral versus injectable semaglutide therapy. A patient receiving the 2.4 mg subcutaneous injection can transition to the 25 mg oral tablet by taking their first pill one week after their final weekly injection. A patient taking the 25 mg tablet can transition to the 2.4 mg injection by administering their first shot on the day immediately following their final tablet.
The tablet and the injection are not interchangeable milligram-for-milligram. The label establishes specific transition steps instead of an equivalence between the two doses. The label gives switching steps rather than a milligram-for-milligram equivalence, so any change between the two forms is a prescriber's decision. For adults with type 2 diabetes who experience an inadequate response to Wegovy tablets, the label instructs clinicians to consider alternative therapies, including switching to Wegovy injection.
The label says that use with other semaglutide-containing products, or with any other GLP-1 receptor agonist, is not recommended. Other oral semaglutide products, including Rybelsus and Ozempic tablets, are indicated solely for type 2 diabetes and cardiovascular risk reduction in diabetes, not for chronic weight management. Readers can review those distinctions in our analysis of Wegovy pill vs Rybelsus.
Wegovy Pill vs Injection Cost and Coverage
Prescription costs for the Wegovy pill and injection depend on whether a patient pays out of pocket through manufacturer cash programs or uses health insurance. According to self-pay cash prices published by NovoCare Pharmacy, pricing for the oral tablet varies by dose strength. The 1.5 mg dose costs $149 per month, the 4 mg dose costs $199 per month, and the 9 mg and 25 mg maintenance doses cost $299 per month, where one month supplies a bottle of 30 tablets.
Novo Nordisk advertises a savings offer for the tablet to pay as little as $25 per month, subject to a maximum savings of $100 per month for up to three months, with government beneficiaries excluded. For the injection, NovoCare Pharmacy lists an introductory price of $199 per month for 0.25 mg and 0.5 mg pens for patients new to the savings offer, valid for two monthly fills through 31 December 2026. Subsequent fills for 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, or 2.4 mg pens cost $349 per month for a box of four pens, while Wegovy HD 7.2 mg costs $399 per month.
The NovoCare Pharmacy page carries no effective or update date, and Novo Nordisk states that it may modify or cancel these self-pay programs at any time. Patients must verify current cash prices directly on the NovoCare page before purchasing, or consult our guide on Wegovy pill costs. Coverage under commercial insurance plans depends on each individual plan formulary, which patients must check directly with their insurer.
Medicare beneficiaries have access to specific terms through the CMS Medicare GLP-1 Bridge demonstration, which operates between 1 July 2026 and 31 December 2027. Under this demonstration, eligible beneficiaries pay a $50 copay for weight management therapies. The eligible drug list includes Wegovy in both injection and tablet forms, Foundayo, and Zepbound in the KwikPen formulation only.
CMS states that the Part D deductible does not apply to the Bridge copay, that no part of it counts towards TrOOP costs, and that no low-income subsidy is provided.
Who Each Form Suits
Selecting between the oral tablet and the subcutaneous pen depends on personal tolerance for daily morning fasting versus weekly injections. The Wegovy tablet suits adult patients who refuse needle-based injections and can commit to a disciplined morning schedule. Taking a daily pill requires waking up, swallowing one tablet with plain water, and waiting 30 minutes before consuming breakfast, coffee, or other morning prescription medications.
The subcutaneous pen suits individuals who prefer weekly administration without daily dietary interruptions. A single weekly injection can be administered at any hour of the day, with or without meals, which accommodates irregular schedules. The injection also carries two indications the tablet does not: patients aged 12 and older with obesity, and noncirrhotic MASH with moderate to advanced liver fibrosis in adults, under accelerated approval.
The Verdict
Both formulations share important safety parameters detailed in their joint prescribing information. Both carry a boxed warning regarding rodent thyroid C-cell tumors and are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Contraindications also include prior serious hypersensitivity reactions to semaglutide or any product excipients.
Warnings named in the label include pancreatitis, acute gallbladder disease, hypoglycemia, acute kidney injury due to volume depletion, severe gastrointestinal adverse reactions, hypersensitivity reactions, diabetic retinopathy complications in patients with type 2 diabetes, heart rate increase, and pulmonary aspiration during general anesthesia or deep sedation. Routine calcitonin monitoring or thyroid ultrasound is of uncertain value for early detection of medullary thyroid carcinoma.
Drug interactions also require clinical oversight. When a single 600 microgram dose of levothyroxine was administered with oral semaglutide, total thyroxine exposure increased by 33%, though maximum concentration was unchanged. No clinically significant pharmacokinetic differences were observed when oral semaglutide was co-administered with omeprazole, lisinopril, S-warfarin, R-warfarin, metformin, digoxin, ethinyl estradiol, levonorgestrel, furosemide, or rosuvastatin. For more on managing side effects, see our guide on semaglutide side effects and our review of Ozempic vs Wegovy.
To choose between the tablet and the injection for your routine, review your medical history, morning schedule, and insurance formulary with a licensed healthcare provider.
Related
- Wegovy Pill Overview and Approval Details
- Wegovy Pill Pricing and Insurance Coverage
- How to Take the Wegovy Pill Step by Step
- Wegovy Pill vs Rybelsus Differences
- Semaglutide Side Effects and Safety Warnings
- Ozempic vs Wegovy Approved Uses and Dosing
Frequently Asked Questions
Is the Wegovy pill as effective as the injection?
No head-to-head randomized trial exists to prove whether the pill works as well as the injection. In the 64-week OASIS 4 trial, the 25 mg tablet delivered a mean body weight change of -13.6% compared to -2.4% on placebo across all randomized patients, and 16.6% among those adhering to treatment. Novo Nordisk describes that result as similar to injectable Wegovy 2.4 mg, but that claim is a cross-trial comparison rather than a head-to-head trial finding. The injection also holds pediatric and liver indications that the tablet does not have.
Is the Wegovy pill cheaper than the injection?
For self-pay patients at NovoCare Pharmacy, the maintenance dose of the pill costs less than the maintenance dose of the pen. The 25 mg tablet is listed at $299 per month, whereas the 2.4 mg injection costs $349 per month after introductory pricing. Lower tablet titration doses run $149 for 1.5 mg and $199 for 4 mg, while introductory injection pricing is $199 per month for two fills. However, NovoCare prices carry no effective date and can change at any time. Insured copays depend on individual plan formularies, while the Medicare GLP-1 Bridge program caps eligible copays at $50 for both.
Can I switch from the Wegovy injection to the pill?
The prescribing information allows switching between the two forms using specific timing rules. A patient taking the 2.4 mg injection can start the 25 mg tablet one week after their final injection. A patient taking the 25 mg tablet can take their first 2.4 mg injection the day after their last tablet. The two formulations are not interchangeable milligram-for-milligram, and the label gives transition steps rather than a dose equivalence. A licensed prescriber must evaluate any transition, and the label does not recommend combining Wegovy with other semaglutide products or other GLP-1 receptor agonists.
Why does the pill have to be taken daily when the injection is weekly?
The label sets different rules for the two forms. Oral semaglutide tablets have an absolute bioavailability of roughly 1% to 2%, compared with 89% for subcutaneous injection, and reach maximum concentration about 1 hour after an oral dose rather than 1 to 3 days. The label instructs that the tablet be taken once daily, in the morning, on an empty stomach, with no more than 4 ounces of water, and that nothing else be taken by mouth for at least 30 minutes. The injection is given once weekly, on the same day each week, at any time of day, with or without meals. The label does not state what happens if the tablet's conditions are not met.
Does the Wegovy pill have fewer side effects than the injection?
Published clinical trial data does not establish whether the pill causes fewer side effects than the pen because no head-to-head trial exists. In Study 7, adverse reactions caused 6.8% of patients taking the 25 mg tablet to discontinue treatment, compared to 5.9% on placebo. Both formulations share the same boxed warning regarding rodent thyroid C-cell tumors and carry identical warnings for pancreatitis, gallbladder disease, and severe gastrointestinal symptoms.
Which reaches the full dose faster, the pill or the injection?
The Wegovy pill reaches its recommended maintenance dose faster than the injection if dose escalation proceeds on schedule. The tablet titration schedule requires 90 days of stepped escalation across three lower doses before starting 25 mg on day 91. The injection requires 16 weeks of stepped titration across four lower doses before reaching the 2.4 mg maintenance dose at week 17. On both formulations, a prescriber may consider delaying dose escalation if a patient experiences tolerability issues during titration.